LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 7 of total 7

Search options

  1. Article ; Online: Two cancer stem cell-targeted therapies in clinical trials as viewed from the standpoint of the cancer stem cell model.

    Caras, Ingrid W

    Stem cells translational medicine

    2020  Volume 9, Issue 8, Page(s) 821–826

    Abstract: A key implication of the cancer stem cell model is that for a cancer therapy to be curative, it is imperative to eliminate the cancer stem cells (CSCs) that drive tumor progression. The California Institute for Regenerative Medicine is supporting two ... ...

    Abstract A key implication of the cancer stem cell model is that for a cancer therapy to be curative, it is imperative to eliminate the cancer stem cells (CSCs) that drive tumor progression. The California Institute for Regenerative Medicine is supporting two novel approaches that target CSCs, one an antibody-mediated immunotherapy targeting CD47 and the other an antibody targeting ROR1. This article summarizes the evidence that CSCs are targeted and discusses the results of early clinical trials within the context of the CSC model.
    MeSH term(s) Clinical Trials as Topic/standards ; Humans ; Immunotherapy/methods ; Neoplasms/therapy ; Neoplastic Stem Cells/pathology
    Language English
    Publishing date 2020-04-12
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2642270-0
    ISSN 2157-6580 ; 2157-6564
    ISSN (online) 2157-6580
    ISSN 2157-6564
    DOI 10.1002/sctm.19-0424
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Two cancer stem cell‐targeted therapies in clinical trials as viewed from the standpoint of the cancer stem cell model

    Ingrid W. Caras

    Stem Cells Translational Medicine, Vol 9, Iss 8, Pp 821-

    2020  Volume 826

    Abstract: Abstract A key implication of the cancer stem cell model is that for a cancer therapy to be curative, it is imperative to eliminate the cancer stem cells (CSCs) that drive tumor progression. The California Institute for Regenerative Medicine is ... ...

    Abstract Abstract A key implication of the cancer stem cell model is that for a cancer therapy to be curative, it is imperative to eliminate the cancer stem cells (CSCs) that drive tumor progression. The California Institute for Regenerative Medicine is supporting two novel approaches that target CSCs, one an antibody‐mediated immunotherapy targeting CD47 and the other an antibody targeting ROR1. This article summarizes the evidence that CSCs are targeted and discusses the results of early clinical trials within the context of the CSC model.
    Keywords cancer stem cells ; clinical trials ; drug target ; leukemia ; immunotherapy ; Medicine (General) ; R5-920 ; Cytology ; QH573-671
    Language English
    Publishing date 2020-08-01T00:00:00Z
    Publisher Oxford University Press
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  3. Article ; Online: A stem cell journey in ophthalmology: From the bench to the clinic.

    Caras, Ingrid W / Collins, Lila R / Creasey, Abla A

    Stem cells translational medicine

    2021  Volume 10, Issue 12, Page(s) 1581–1587

    Abstract: Debilitating diseases of the eye represent a large unmet medical need potentially addressable with stem cell-based approaches. Over the past decade, the California Institute for Regenerative Medicine (CIRM) has funded and supported the translation, from ... ...

    Abstract Debilitating diseases of the eye represent a large unmet medical need potentially addressable with stem cell-based approaches. Over the past decade, the California Institute for Regenerative Medicine (CIRM) has funded and supported the translation, from early research concepts to human trials, of therapeutic stem cell approaches for dry age-related macular degeneration, retinitis pigmentosa, and limbal stem cell deficiency. This article chronicles CIRM's journey in the ophthalmology field and discusses some key challenges and questions that were addressed along the way as well as questions that remain.
    MeSH term(s) Humans ; Ophthalmology ; Regenerative Medicine ; Stem Cell Transplantation ; Stem Cells
    Language English
    Publishing date 2021-09-13
    Publishing country England
    Document type Journal Article
    ZDB-ID 2642270-0
    ISSN 2157-6580 ; 2157-6580
    ISSN (online) 2157-6580
    ISSN 2157-6580
    DOI 10.1002/sctm.21-0239
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: A stem cell journey in ophthalmology

    Ingrid W. Caras / Lila R. Collins / Abla A. Creasey

    Stem Cells Translational Medicine, Vol 10, Iss 12, Pp 1581-

    From the bench to the clinic

    2021  Volume 1587

    Abstract: Abstract Debilitating diseases of the eye represent a large unmet medical need potentially addressable with stem cell‐based approaches. Over the past decade, the California Institute for Regenerative Medicine (CIRM) has funded and supported the ... ...

    Abstract Abstract Debilitating diseases of the eye represent a large unmet medical need potentially addressable with stem cell‐based approaches. Over the past decade, the California Institute for Regenerative Medicine (CIRM) has funded and supported the translation, from early research concepts to human trials, of therapeutic stem cell approaches for dry age‐related macular degeneration, retinitis pigmentosa, and limbal stem cell deficiency. This article chronicles CIRM's journey in the ophthalmology field and discusses some key challenges and questions that were addressed along the way as well as questions that remain.
    Keywords cellular therapy ; clinical translation ; retina ; retinal pigmented epithelium ; stem cells ; Medicine (General) ; R5-920 ; Cytology ; QH573-671
    Language English
    Publishing date 2021-12-01T00:00:00Z
    Publisher Oxford University Press
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  5. Article: Proceedings: debilitating eye diseases.

    Caras, Ingrid W / Littman, Neil / Abo, Arie

    Stem cells translational medicine

    2014  Volume 3, Issue 12, Page(s) 1393–1397

    Abstract: Debilitating eye diseases such as age-related macular degeneration and retinitis pigmentosa currently represent a large unmet medical need that could potentially be addressed by stem cell therapy. A number of novel stem cell-based cellular therapies are ... ...

    Abstract Debilitating eye diseases such as age-related macular degeneration and retinitis pigmentosa currently represent a large unmet medical need that could potentially be addressed by stem cell therapy. A number of novel stem cell-based cellular therapies are now under development to treat a variety of eye diseases. The approaches being taken by the California Institute for Regenerative Medicine, together with its grantees, are discussed.
    MeSH term(s) Cell- and Tissue-Based Therapy/methods ; Humans ; Retinitis Pigmentosa/therapy ; Stem Cell Transplantation
    Language English
    Publishing date 2014-12
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2642270-0
    ISSN 2157-6580 ; 2157-6564
    ISSN (online) 2157-6580
    ISSN 2157-6564
    DOI 10.5966/sctm.2014-0221
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu.

    Tai, Yu-Tzu / Dillon, Myles / Song, Weihua / Leiba, Merav / Li, Xian-Feng / Burger, Peter / Lee, Alfred I / Podar, Klaus / Hideshima, Teru / Rice, Audie G / van Abbema, Anne / Jesaitis, Lynne / Caras, Ingrid / Law, Debbie / Weller, Edie / Xie, Wanling / Richardson, Paul / Munshi, Nikhil C / Mathiot, Claire /
    Avet-Loiseau, Hervé / Afar, Daniel E H / Anderson, Kenneth C

    Blood

    2007  Volume 112, Issue 4, Page(s) 1329–1337

    Abstract: Currently, no approved monoclonal antibody (mAb) therapies exist for human multiple myeloma (MM). Here we characterized cell surface CS1 as a novel MM antigen and further investigated the potential therapeutic utility of HuLuc63, a humanized anti-CS1 mAb, ...

    Abstract Currently, no approved monoclonal antibody (mAb) therapies exist for human multiple myeloma (MM). Here we characterized cell surface CS1 as a novel MM antigen and further investigated the potential therapeutic utility of HuLuc63, a humanized anti-CS1 mAb, for treating human MM. CS1 mRNA and protein was highly expressed in CD138-purified primary tumor cells from the majority of MM patients (more than 97%) with low levels of circulating CS1 detectable in MM patient sera, but not in healthy donors. CS1 was expressed at adhesion-promoting uropod membranes of polarized MM cells, and short interfering RNA (siRNA) targeted to CS1 inhibited MM cell adhesion to bone marrow stromal cells (BMSCs). HuLuc63 inhibited MM cell binding to BMSCs and induced antibody-dependent cellular cytotoxicity (ADCC) against MM cells in dose-dependent and CS1-specific manners. HuLuc63 triggered autologous ADCC against primary MM cells resistant to conventional or novel therapies, including bortezomib and HSP90 inhibitor; and pretreatment with conventional or novel anti-MM drugs markedly enhanced HuLuc63-induced MM cell lysis. Administration of HuLuc63 significantly induces tumor regression in multiple xenograft models of human MM. These results thus define the functional significance of CS1 in MM and provide the preclinical rationale for testing HuLuc63 in clinical trials, either alone or in combination.
    MeSH term(s) Animals ; Antibodies, Monoclonal/pharmacology ; Antibody-Dependent Cell Cytotoxicity/drug effects ; Antigens, Neoplasm ; Bone Marrow ; Cell Adhesion/drug effects ; Humans ; Mice ; Multiple Myeloma/drug therapy ; Multiple Myeloma/pathology ; RNA, Messenger/analysis ; Receptors, Immunologic/genetics ; Receptors, Immunologic/immunology ; Signaling Lymphocytic Activation Molecule Family ; Stromal Cells ; Tumor Cells, Cultured ; Xenograft Model Antitumor Assays
    Chemical Substances Antibodies, Monoclonal ; Antigens, Neoplasm ; RNA, Messenger ; Receptors, Immunologic ; SLAMF7 protein, human ; Signaling Lymphocytic Activation Molecule Family
    Language English
    Publishing date 2007-09-28
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 80069-7
    ISSN 1528-0020 ; 0006-4971
    ISSN (online) 1528-0020
    ISSN 0006-4971
    DOI 10.1182/blood-2007-08-107292
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.140: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 364: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article: Expression of the zinc transporter ZnT4 is decreased in the progression from early prostate disease to invasive prostate cancer.

    Henshall, Susan M / Afar, Daniel E H / Rasiah, Krishan K / Horvath, Lisa G / Gish, Kurt / Caras, Ingrid / Ramakrishnan, Vanitha / Wong, Melanie / Jeffry, Ursula / Kench, James G / Quinn, David I / Turner, Jennifer J / Delprado, Warick / Lee, C-Soon / Golovsky, David / Brenner, Phillip C / O'Neill, Gordon F / Kooner, Raji / Stricker, Phillip D /
    Grygiel, John J / Mack, David H / Sutherland, Robert L

    Oncogene

    2003  Volume 22, Issue 38, Page(s) 6005–6012

    Abstract: We have utilized oligonucleotide microarrays to identify novel genes of potential clinical and biological importance in prostate cancer. RNA from 74 prostate cancers and 164 normal body samples representing 40 different tissues were analysed using a ... ...

    Abstract We have utilized oligonucleotide microarrays to identify novel genes of potential clinical and biological importance in prostate cancer. RNA from 74 prostate cancers and 164 normal body samples representing 40 different tissues were analysed using a customized Affymetrix GeneChip oligonucleotide microarray representative of over 90% of the expressed human genome. The gene for the zinc transporter ZnT4 was one of several genes that displayed significantly higher expression in prostate cancer compared to normal tissues from other organs. A polyclonal antipeptide antibody was used to demonstrate ZnT4 expression in the epithelium of all 165 elements of benign and 326 elements of localized prostate cancers examined and in nine of 10 advanced prostate cancer specimens by immunohistochemistry. Interestingly, decreased intensity of ZnT4 immunoreactivity occurred in the progression from benign to invasive localized prostate cancer and to metastatic disease. Immunofluorescence analysis and surface biotinylation studies of cells expressing ZnT4 localised the protein to intracellular vesicles and to the plasma membrane. These findings are consistent with a role for ZnT4 in vesicular transport of zinc to the cell membrane and potentially in efflux of zinc in the prostate.
    MeSH term(s) Adolescent ; Adult ; Amino Acid Sequence ; Carrier Proteins/genetics ; Carrier Proteins/metabolism ; Cation Transport Proteins ; Cell Membrane/metabolism ; Disease Progression ; Gene Expression Regulation, Neoplastic ; Humans ; Male ; Molecular Sequence Data ; Oligonucleotide Array Sequence Analysis ; Prostate/physiology ; Prostatic Hyperplasia/genetics ; Prostatic Hyperplasia/metabolism ; Prostatic Hyperplasia/pathology ; Prostatic Neoplasms/genetics ; Prostatic Neoplasms/metabolism ; Prostatic Neoplasms/pathology ; Reference Values ; Transport Vesicles/metabolism
    Chemical Substances Carrier Proteins ; Cation Transport Proteins ; SLC30A4 protein, human
    Language English
    Publishing date 2003-09-04
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 639046-8
    ISSN 1476-5594 ; 0950-9232
    ISSN (online) 1476-5594
    ISSN 0950-9232
    DOI 10.1038/sj.onc.1206797
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2218: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top